Lions Gate Entertainment Corp. (NYSE: LGF-Free Report) will team up with Chinese e-commerce giant Alibaba Group to provide streaming services in Mainland China. Lionsgate Entertainment World (LGEW), the subscription channel, will be available through Alibaba's latest generation of set-top boxes.

Through LGEW, customers will have access to several Hollywood smash hits including Lions Gate's blockbuster franchises The Hunger Games,Twilight and the recently released first installment of the Divergent franchise. Popular television series like Mad Men and Weeds will be also available, whereas series like Rosemary's Baby and The Royals will premiere in China on LGEW.

Additionally, customers will be able to enjoy behind-the-scenes footage, features and extra premium content which are not available anywhere else across China. Moreover, subscribers will get VIP membership benefits like special merchandise gifts and screening invitations. The service is slated for an August launch.

Mainland China is one of the fastest growing markets for movie and television content. The collaboration will provide Lions Gate with an opportunity to gain better access to this lucrative market. Moreover, Alibaba's expertise in the digital entertainment market and Lions Gate's top class content make an intriguing combination.

Lions Gate is fast emerging as a leading player in the media industry which boasts of stalwarts likeThe Walt Disney Co. (NYSE: DIS-Free Report), Twenty-First Century Fox, Inc. (Nasdaq: FOXA-Free Report) and CBS Corp. (NYSE: CBS-Free Report). With franchises like The Hunger Games and Divergent, the studio has achieved tremendous success. Lions Gate acquired Summit Entertainment in 2012, which has given it the rights for the hugely popular young-adult fantasy themed Twilight series.

The studio is grabbing every possible opportunity to expand its presence and soon might become a recognizable power within the media circle.

The upgrade came on the heels of Hospira's recently completed Orchid facility buy. Earlier in the month, the company announced that it has completed the acquisition of the penem and penicillin active pharmaceutical ingredient manufacturing unit and an associated research and development facility from India-based Orchid Chemicals & Pharmaceuticals Ltd. for around $218 million. The deal was first announced in 2012. (Read more: HOSPIRA COMPLETES ORCHID FACILITY BUY).

Moreover, Hospira delivered impressive first quarter 2014 earnings of 60 cents per share, beating the Zacks Consensus Estimate by 11 cents and year-ago earnings by 15.4%. The first quarter earnings beat was aided by higher revenues.

Hospira's Specialty Injectable Pharmaceuticals segment has over the past several quarters contributed the majority of revenues. The segment performed well in the first quarter too. Favorable pricing as well as volume led to the strong segmental performance. Expansion in volume was driven by continued supply recovery along with competitor supply issues in the U.S. Segmental sales climbed 9.9% (up 11.1% at constant currency) to $716.3 million.

The Zacks Consensus Estimate for 2014 is currently pegged at $2.21. It is on the higher end of the company's guidance range of $2.00 to $2.25 per share.

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.